Genmab — Oktober 2019
-
God morgen. :-). Lidt J&J facts fra i går. https://m.firstwordpharma.com/johnson-johnson-boosts-annual-guidance-stelara-leads-growth-third-quarter-sales
-
1 million i omsætning pr. minut.
-
-
-
Synes også den grafiske fremstilling af salgsudvikling ser spændende ud
- er lidt talnørd så er der mon en der ved hvor kan jeg se de enkelte tal der indgår i søjlerne -
pensionisten: tak for info
-
-
H.C. Wainwrigh
t raises target price to USD 25 from USD 24 -
AQR har reduceret short fra 1,29% til 1,19%
-
Nektar Therapeutics starts a new trial, also with Dara https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-announces-initiation-first-human-phase-1
-
In a preclinical lymphoma model where single agent daratumumab was ineffective, NKTR-255 treatment, in combination with daratumumab, increased NK cell numbers and activity in bone marrow tissue and enhanced ADCC-mediated tumor cell clearance in the bone marrow compartment.4
-
Nektar havde denne på AACR
https://www.nektar.com/application/files/7215/5420/5270/AACR2019-ABS3265-Final.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind